Source comparison
Head-to-Head Mechanistic Comparison
The critical research distinction: Epithalon works upstream of cellular senescence — it delays the onset of replicative senescence by extending telomere maintenance (addressing the root cause of the Hayflick limit). MOTS-C works within existing cells — it impr
This comparison does not assign a generated winner or score.
- The critical research distinction: Epithalon works upstream of cellular senescence — it delays the onset of replicative senescence by extending telomere maintenance (addressing the root cause of the Hayflick limit). MOTS-C works within existing cells — it improves the metabolic function of post-mitotic and slowly dividing aged cells without restoring their replicative capacity. Neither compound is a direct senolytic (eliminating existing senescent cells), though both reduce SASP output indirectly.
- Temporal profiles in aged rodent models: Epithalon requires long-term treatment (6–12 months) to demonstrate maximum telomere/epigenetic effects — consistent with telomere elongation kinetics (telomeres elongate ~30–50 bp/cell division; significant length change requires multiple cell generations). MOTS-C shows rapid metabolic effects within 1–4 weeks (AMPK activation is acute; OCR improvements measurable at 2 weeks; glucose tolerance improvement at 4 weeks) — consistent with enzymatic/signalling rather than epigenetic mechanisms. Tissue targeting: Epithalon effects are most pronounced in high-turnover tissues (skin/fibroblasts, immune cells, epithelium) where replicative senescence accumulates fastest. MOTS-C effects are most pronounced in post-mitotic high-energy-demand tissues (muscle, heart, brain) where mitochondrial dysfunction dominates age-related decline.